GlycoMimetics, Inc. Board of Directors

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Mr. Harout Semerjian

Mr. Harout Semerjian

CEO, President & Director

Mr. Bruce Johnson

Mr. Bruce Johnson

Senior VP & Chief Commercial Officer

Mr. Shantha Tyavanagimatt Ph.D.

Mr. Shantha Tyavanagimatt Ph.D.

Senior Vice President of Technical Operations

Mr. Christian B. Dinneen-Long

Mr. Christian B. Dinneen-Long

General Counsel & Company Secretary

Ms. Rachel K. King

Ms. Rachel K. King

Co-Founder & Director

Mr. Chinmaya Rath

Mr. Chinmaya Rath

Senior VP & Chief Business Officer

Ms. Stephanie R. Irish CPA

Ms. Stephanie R. Irish CPA

Vice President of Accounting

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.